Cancer is a group of heterogeneous diseases caused by uncontrolled cell proliferation and growth. Cancer incidence is predicted to increase in the following two decades.

Cancer causes 20% of deaths in Europe, representing the most important cause of death and morbidity after cardiovascular diseases. Many types of cancer may be prevented and early detection increases the chance of cure substantially. As cancer is one of the main health priorities, key areas of research and improvement include prevention, early detection, diagnosis and treatment, quality of life of cancer patients and survivors. Factors such as expanded development of new cancer therapies, long-term pharmacological treatment and increased survival due to improved care can cause increased long-term side effects urging more research in cancer pharmacoepidemiology. Cancer pharmacoepidemiology at CPE includes research to investigate the effects of various medications on cancer risk, response to cancer treatments, and also adverse or long-term effects of pharmacologic agents used to treat cancer.


The research area is led by Shahram Bahmanyar (Publications on PubMed)

Content reviewer: